Alnylam Drug Approval Brings Cardiomyopathy Competition to Pfizer, BridgeBio Pharma

**FDA Approves Alnylam’s Amvuttra for Cardiomyopathy Linked to Transthyretin Amyloidosis**

The U.S. Food and Drug Administration has approved Amvuttra, a drug developed by Alnylam Pharmaceuticals, for the treatment of cardiomyopathy caused by transthyretin amyloidosis (ATTR-CM). This marks an expansion of the drug’s use beyond its initial approval for managing nerve pain associated with the same disease. The new indication positions Amvuttra in a larger market but places it in direct competition with Pfizer’s established therapy, which is widely regarded as the standard of care.

Amvuttra utilizes RNA interference technology to target transthyretin amyloidosis, a rare condition characterized by abnormal protein deposits that can lead to organ damage. With this latest approval, Alnylam aims to address cardiomyopathy symptoms linked to ATTR-CM, broadening its potential patient base. However, the company faces challenges from existing treatments such as Pfizer’s Vyndamax and BridgeBio Pharma’s investigational therapies, which have already gained traction among healthcare providers and patients.

Newsflash | Powered by GeneOnline AI

Source: https://medcitynews.com/2025/03/alnylam-amvuttra-fda-approval-cardiomyopathy-attr-cm-vutrisiran-rnai-alny/

Related posts:

Novartis Nabs First FDA Nod in Rare Kidney Disease, But Apellis Pharma Is on Its Heels Real-Time Brain Imaging Unveils Neural Processing of Stimuli Pharmaceutical Company Valuation Hinges on Five Key Factors, Including Revenue Loss from Patent Expiration Public Health Updates: Reports Cover Diverse Health Areas, Offering Unbiased Information

Author

Mark Chiang